SCHEMBL277132

SCHEMBL277132

COC(=O)c1ccc(C(=O)NN2CCN(C)CC2)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.68
LMNA P02545 2/20 0.68
MAPK1 P28482 1/20 0.68
CYP2D6 P10635 2/20 0.49
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HTT P42858 1/20 0.46
GAA P10253 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
LIPE Q05469 1/20 0.43
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269934 0.87 MAPK1 (0.50) KMT2ALMNAMAPK1ALDH1A1HTT
SCHEMBL276182 0.84 HTT (0.66) KMT2ALMNAMAPK1CYP2D6ALDH1A1
SCHEMBL277360 0.84 KMT2A (0.69) KMT2ALMNAMAPK1CYP2D6ALDH1A1
SCHEMBL279590 0.82 KMT2A (0.71) KMT2ALMNAMAPK1CYP2D6ALDH1A1
SCHEMBL21625722 0.81 KMT2A (0.69) KMT2ALMNAMAPK1CYP2D6ALDH1A1
SCHEMBL24671588 0.76 LMNA (0.45) KMT2ALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL70027 0.75 NPSR1 (0.67) KMT2ALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL21625724 0.73 KMT2A (0.52) KMT2ALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL278453 0.73 HDAC3 (0.49) KMT2ALMNAMAPK1ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL21625738 0.72 KMT2A (0.51) KMT2ALMNAMAPK1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
CN-101076519-A Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL IND LTD (JP) 2007-11-21 CN disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885LMNA 1745/4885MAPK1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.